Cited by 10Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177Lu- and 90Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor

Todorović-Tirnanić, Mila, Kaemmerer, Daniel, Prasad, Vikas, Hommann, Merten, Baum, Richard P.·2013·Recent Results in Cancer Research

Abstract

Aim The aim of this chapter is to present the results of the first intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy (PRRNT) with (90)Y- and (177)Lu-DOTATOC using a handheld gamma probe and comparison with the findings of preoperative (68)Ga-DOTATOC PET/CT in a patient with a metastatic neuroendocrine tumor (NET) of the ileum.Materials and methods A 56-year-old female patient, treated twice by PRRNT, was admitted for the third cycle and subsequent surgery. Before operation, the following studies were performed for restaging after the second cycle of PRRNT: (99m)Tc-MAG3 + TER, (99m)Tc-DTPA + GFR, abdominal ultrasonography, MRI of the abdomen, (68)Ga-DOTATOC PET/CT as well as (18)F-fluoride PET/CT. Serum tumor markers were measured before and after PRRNT. Tandem PRRNT was performed using 3000 MBq (90)Y-DOTATOC and 6000 MBq (177)Lu-DOTATOC. Whole-body scintigrams were obtained at 23 and 43 h. Five days after PRRNT, the patient was operated using a handheld gamma probe. Immunohistochemistry and histopathology of the resected tissue were performed.Results Tandem PRRNT was very well tolerated by the patient. Before PRRNT, (68)Ga-DOTATOC PET/CT revealed the primary tumor in the ileocoecal region as well as bilobular liver metastases and a right iliac bone lesion (osteoblastic on (18)F-fluoride PET/CT). Compared with the previous findings, there was good therapy response (partial remission of the tumor lesions). No nephrotoxicity was observed. Serum chromogranin A (836 μg/l, n < 100) and serotonin (852 μg/l, n < 200) were strongly elevated. Posttherapy scans showed intense uptake in metastases and the primary tumor. Intraoperative gamma probe detected-in addition to the known lesions-bilateral ovarian metastases not visualized by (68)Ga-DOTATOC PET/CT. Bilateral adnexectomy, right hemicolectomy, excision of hepatic metastases in S3, and partial resection of peritoneum were performed. Histopathology confirmed metastases in both ovaries.Conclusions Gamma probe-guided surgery after (177)Lu PRRNT is feasible and appears to be more sensitive than (68)Ga-DOTATOC PET/CT. This technique might aid the surgeon in achieving more complete tumor resection through intraoperative detection of very small lesions (<5 mm) directly after PRRNT.

Integrity signals

Registry

Crossref · 10.1007/978-3-642-27994-2_28

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Todorović-Tirnanić, M., Kaemmerer, D., Prasad, V., Hommann, M., & Baum, R. P.
Affiliations
  • University of Belgrade (RS)
  • Zentralklinik Bad Berka (DE)
Corresponding author
Baum, Richard P.
Venue
Recent Results in Cancer Research
Published
2012-08-24
Volume
194
Pages
487-496
ISSN
0080-0015 (ISSN-L)
OpenAlex
W246736197
Cited by
10
References
10
Citations by year
2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 2 · 2015: 3
FWCI
4.19
Type
book chapter
Language
en
Open access
closed
Locations
  • Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
peptide receptor radionuclide therapy, 177Lu-DOTATOC, 90Y-DOTATOC, hand-held gamma probe, intraoperative imaging, neuroendocrine tumors, ileal neuroendocrine tumor, liver metastasis, ovarian metastasis, 68Ga-DOTATOC PET/CT
MeSH terms
Female, Humans, Intraoperative Period, Liver Neoplasms, Lutetium, Middle Aged, Radioisotopes, Tomography, X-Ray Computed, Octreotide, Receptors, Somatostatin, Neuroendocrine Tumors, Radiopharmaceuticals, Positron-Emission Tomography, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review